Read Ophthalmology Times' extensive coverage from the 2007 annual meeting in New Orleans, USA.
Crafting an international database for retinopathy of prematurity
Intercontinental collaboration is key to unlocking ROP in our lifetime
Higher Molar Dose and Its Translation into Clinical Practice
US FDA approves continuous delivery ranibizumab treatment (Susvimo, Genentech) for diabetic macular oedema
Previously, Susvimo was called the Port Delivery System with ranibizumab in the United States
Nuance Audio hearing aid glasses receive concurrent CE Mark and FDA approval
The hearing aid glasses from EssilorLuxottica received CE marking under the Medical Devices Regulation of the EMA
Ocugen, Inc. receives European Medicines Agency ATMP designation for new gene therapy
OCU400 is the first gene therapy from the biotechnology company to move forward into Phase 3 with a broad retinitis pigmentosa (RP) indication
European Medicines Agency CHMP adopts positive opinions for two aflibercept biosimilars
Pavblu and Skojoy, both from Amgen, are indicated for the treatment of neovascular age-related macular degeneration
